大象传媒

India, with the second-highest number of Covid-19 infections in the world after the United States, has recently begun a vaccination rollout that promises to reach 300 million people by the summer. Millions of doses of two vaccines - Covishield and Covaxin - have been shipped across the country. Covishield is a version of the Oxford-AstraZeneca vaccine that is manufactured in India. Covaxin has been developed by the Indian company Bharat Biotech and the regulator's emergency approval came before the completion of Phase 3 clinical trials, which would provide information on the effectiveness of the vaccine .

Medical ethicist and health policy expert Anant Bhan explains the issues arising from the lack of effectiveness data for Covaxin.

Photo: A medical worker inoculates a staff member with Covid-19 coronavirus vaccine at the G.B. Pant hospital in Srinagar, India Credit: AF